This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
Wells Fargo Keeps Their Hold Rating on Resmed (RMD)
Wells Fargo analyst Nathan Treybeck maintained a Hold rating on Resmed on May 29 and set a price target of $227.00. The company’s shares closed last Friday at $190.57.
Claim 55% Off TipRanks
- Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis.
- Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter
According to TipRanks, Treybeck is an analyst with an average return of -1.7% and a 34.21% success rate.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Resmed with a $264.56 average price target.
Based on Resmed’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $1.43 billion and a net profit of $398.73 million. In comparison, last year the company earned a revenue of $1.29 billion and had a net profit of $365.04 million
Read More on RMD:
Disclaimer & DisclosureReport an Issue
- ResMed Targets Circadian Data With New Wearable Trial: What Investors Should Watch
- ResMed, Oura partner to expand access to sleep health education
- Analyst Maintains Hold on ResMed as Noctrix Acquisition Offers Limited Incremental Growth Amid Competitive Risks
- The Week That Was, The Week Ahead: Macro and Markets, May 10
- ResMed Earnings Call Highlights Margin Strength, Growth
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
